Geode Capital Management LLC Acquires 24,530 Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR)

Geode Capital Management LLC lifted its position in shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) by 174.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 38,596 shares of the company’s stock after acquiring an additional 24,530 shares during the quarter. Geode Capital Management LLC owned approximately 0.63% of Monopar Therapeutics worth $849,000 at the end of the most recent reporting period.

Separately, JPMorgan Chase & Co. bought a new stake in Monopar Therapeutics in the fourth quarter valued at approximately $45,000. Institutional investors own 1.83% of the company’s stock.

Analyst Upgrades and Downgrades

MNPR has been the subject of a number of research analyst reports. Jones Trading reaffirmed a “hold” rating on shares of Monopar Therapeutics in a research note on Wednesday, April 2nd. Piper Sandler reaffirmed an “overweight” rating and set a $76.00 price objective on shares of Monopar Therapeutics in a research report on Wednesday, March 19th. Finally, HC Wainwright reissued a “buy” rating and issued a $40.00 target price on shares of Monopar Therapeutics in a research report on Tuesday, April 1st.

Insider Buying and Selling at Monopar Therapeutics

In other Monopar Therapeutics news, major shareholder Tactic Pharma Llc sold 33,334 shares of the company’s stock in a transaction on Wednesday, April 2nd. The shares were sold at an average price of $35.00, for a total transaction of $1,166,690.00. Following the sale, the insider now owns 822,255 shares of the company’s stock, valued at approximately $28,778,925. This represents a 3.90 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 34.90% of the company’s stock.

Monopar Therapeutics Stock Up 3.2 %

Shares of MNPR stock opened at $43.15 on Friday. The company has a market cap of $263.78 million, a P/E ratio of -21.90 and a beta of 1.01. Monopar Therapeutics Inc. has a twelve month low of $1.72 and a twelve month high of $54.30. The business has a fifty day simple moving average of $35.65 and a 200 day simple moving average of $29.49.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings results on Monday, March 31st. The company reported ($2.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($1.87). As a group, equities research analysts anticipate that Monopar Therapeutics Inc. will post -1.65 earnings per share for the current fiscal year.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.